The application of Everolimus in breast cancer has been extensively studied in HR+ BC, and research is gradually progressing in HER2+ BC, particularly in patients resistant to HER2-targeted therapies such as trastuzumab [174]. This evidence concerns the gene ERBB2 and breast carcinoma.